Journal of Diabetes Research

Journal of Diabetes Research / 2017 / Article

Research Article | Open Access

Volume 2017 |Article ID 6403539 | 7 pages | https://doi.org/10.1155/2017/6403539

Repurposing Lesogaberan to Promote Human Islet Cell Survival and β-Cell Replication

Academic Editor: Peter Thule
Received12 May 2017
Accepted26 Jul 2017
Published05 Sep 2017

Abstract

The activation of β-cell’s A- and B-type gamma-aminobutyric acid receptors (GABAA-Rs and GABAB-Rs) can promote their survival and replication, and the activation of α-cell GABAA-Rs promotes their conversion into β-cells. However, GABA and the most clinically applicable GABA-R ligands may be suboptimal for the long-term treatment of diabetes due to their pharmacological properties or potential side-effects on the central nervous system (CNS). Lesogaberan (AZD3355) is a peripherally restricted high-affinity GABAB-R-specific agonist, originally developed for the treatment of gastroesophageal reflux disease (GERD) that appears to be safe for human use. This study tested the hypothesis that lesogaberan could be repurposed to promote human islet cell survival and β-cell replication. Treatment with lesogaberan significantly enhanced replication of human islet cells in vitro, which was abrogated by a GABAB-R antagonist. Immunohistochemical analysis of human islets that were grafted into immune-deficient mice revealed that oral treatment with lesogaberan promoted human β-cell replication and islet cell survival in vivo as effectively as GABA (which activates both GABAA-Rs and GABAB-Rs), perhaps because of its more favorable pharmacokinetics. Lesogaberan may be a promising drug candidate for clinical studies of diabetes intervention and islet transplantation.

1. Introduction

A major goal in diabetes research is to develop agents that can safely promote human β-cell survival and replication. Most mitogens and growth factors that have been shown to promote rodent β-cell replication fail to promote human β-cell replication (reviewed in [1, 2]). β-Cells have been long known to express the GABA synthetic enzyme glutamic acid decarboxylase (GAD), as well as GABAA-Rs and GABAB-Rs [37]. Although GABAA-Rs and GABAB-Rs share GABA as an agonist, these receptors are encoded by distinct gene families and their activation induces different pathways; GABAA-Rs are fast-acting chloride channels and GABAB-Rs are slow-acting G-protein-coupled receptors [8, 9]. Recently, GABA administration has been shown to protect rodent and human β-cells from apoptosis and to promote their replication both in vitro and in vivo [1014]. This response is mediated by both GABAA-R and GABAB-Rs [1012, 14, 15]. GABA-mediated enhancement of β-cell replication did not attenuate after five weeks of GABA treatment and led to an eventual increase in β-cell mass in a nonautoimmune context [14]. Notably, GABA treatment enhanced β-cell replication and survival in newly diabetic NOD mice [11, 16, 17], indicating that GABA-R activation can be beneficial in an autoimmune context even when little β-cell mass remains.

β-Cells express GABAA-Rs and GABAB-Rs [3, 4, 7, 18, 19]. α-Cells express GABAA-Rs but may not express functional GABAB-Rs, while PCR detects GABAB-R transcripts in isolated α-cells (but not the α-cell line α-TC9), a GABAB-R agonist failed to modulate any of the tested α-cell functions [3, 1821]. We are unaware of any evidence of functional GABAB-Rs on δ or PP islet cells. Very recently, long-term treatment with antimalarial drugs that target gephyrin (a protein that participates in GABAA-R transport to the membrane), or treatment with GABA, was shown to promote islet α-cell transdifferentiation into β-cells [22, 23]. This conversion appears to be mediated by GABAA-Rs [22, 23] and not the GABAB-Rs that are the focus of this study.

GABA appears safe for human consumption [24] and its inability to pass through the blood-brain barrier (BBB) avoids potential CNS effects. GABA, however, has a relatively low affinity for its receptors, a fast off-rate (presumably so that neurons can quickly respond to the next stimulus), and a short half-life (about 20 minutes in blood [25]) and therefore may be pharmacologically suboptimal. In the clinic, there are many BBB-permeable drugs that can modulate neuronal GABA-Rs and ameliorate CNS disorders such as seizures, anxiety, and insomnia. Their CNS effects, however, raise concerns about their long-term use for the treatment of diabetes. It would be ideal if peripherally restricted GABA-R agonists that were safe for human use could be repurposed for treating diabetes.

Lesogaberan (AZD3355) is a peripherally restricted GABAB-R-specific agonist that was developed for the treatment of GERD [2628]. It has an EC50 of 9 nM (compared to GABA’s EC50 of 160 nM) and a Ki of 5 nM (versus 110 nM for GABA) for GABAB-Rs [26] and a half-life of about 11 hours in peripheral blood [29, 30]. While treatment of GERD patients with lesogaberan (oral 60–240 mg twice daily) for up to 28 days in several phase IIb clinical trials did not result in sufficient beneficial effects, there were no treatment-related serious adverse events, suggesting that lesogaberan may be safe for human use [27, 29, 31]. Here, we tested the potential of repurposing lesogaberan to promote human islet cell survival and β-cell replication. Our findings suggest that targeting GABAB-Rs can promote human β-cell replication and islet cell survival to a similar extent as GABA.

2. Materials and Methods

2.1. Chemicals

Lesogaberan was supplied by AstraZeneca (London, UK). The development and structure of lesogaberan have been previously described [28]. Saclofen, streptozotocin (STZ), and 5-bromo-2-deoxyuridine (BrdU) were purchased from Sigma Aldrich.

2.2. Islet Cell Proliferation Assay

Fresh human islets were obtained from the Integrated Islet Distribution Program (IIDP). The islets (50–75 IEQ/well) were treated in triplicate with, or without, the indicated dosages of lesogaberan in CMRL medium (0.1% glucose, Gibco) containing 10% human AB-type sera (MP Biomedicals, Santa Ana, USA) and 1.5 μCi/ml of 3H-thymidine in the presence or absence of the competitive GABAB-R antagonist saclofen (10−4 M) for 4 days. Islets cultured in medium alone served as controls. The 3H-thymidine uptake in individual wells was measured by β-counter. Data were analyzed by the proliferation index formula: CPM of experimental wells / CPM of controls.

2.3. Analysis of Human β-Cell Replication In Vivo

All animal experiments were approved by UCLA’s Animal Research Committee. NOD/scid mice were injected intraperitoneally with STZ to induce diabetes and implanted with about 2000 human islets under their kidney capsule. The mice were randomized and treated for 12 days with plain water containing 0.8 mg/ml of BrdU as the control or water containing the same dose of BrdU and lesogaberan (0.08 mg/ml) or positive control GABA (6 mg/ml). At the end of treatment, the percentages of BrdU+insulin+ and Ki67+insulin+ β-cells in at least 2000 islet cells of 10 fields (magnification ×400) of each islet graft were determined by immunofluorescence in a blinded manner, as our previous report [12].

2.4. Analysis of Human β-Cell Apoptosis In Vivo

STZ-rendered diabetic NOD/scid mice were implanted with about 2000–3000 human islets under their kidney capsule. The mice were randomized and given plain water or water containing lesogaberan (0.08 mg/ml) or positive control GABA (6 mg/ml). Forty-eight hours later, the percentages of insulin+ β-cells or TUNEL+ apoptotic islet cells in total islet cells within the grafts of individual recipients were determined by immunofluorescence in a blinded manner, as in our previous report [12].

2.5. Statistical Analysis

Data are expressed as the mean ± SEM of individual groups ( mice per group) from two separate experiments. The difference among groups was analyzed by ANOVA and post hoc Fisher’s least significant difference and the difference between groups was determined Student t-test. A value of <0.05 was considered statistically significant.

3. Results

3.1. Lesogaberan Enhances Human Islet Cell Proliferation In Vitro

Human islets were treated with lesogaberan over a dose range in the presence, or absence, of the GABAB-R competitive antagonist saclofen. The effect of drug treatment on islet cell proliferation was determined by 3H-thymidine incorporation. We observed that lesogaberan at 3 nM had a small but nonsignificant promitotic effect, while treatment at higher dosages (10 and 30 nM) led to a 2-3-fold increase in proliferation relative to that of islets cultured in medium alone (Figure 1). Lesogaberan effects were not dose-dependent at the concentrations tested, and this may reflect its bimodal effect that was noted in some early preclinical GERD studies [26], but was not observed in subsequent clinical studies [27, 29, 3133]. The promitotic effect of lesogaberan was blocked by saclofen (Figure 1). Hence, activation of GABAB-Rs enhanced human islet cell proliferation in vitro.

Since β-cells may be the only islet cell type that expresses functional GABAB-Rs and α-cell transdifferentiation would require long-term GABAA-R activation and would not involve 3H-thymidine incorporation into new DNA, the vast majority of the proliferating islet cells are likely to be β-cells. That contention, however, requires verification, which we pursued using quantitative immunohistochemical analysis of β-cells in human xenografts below.

3.2. Oral Lesogaberan Promotes Human β-Cell Replication In Vivo

Next, we quantitatively assessed lesogaberan’s effects on human β-cell replication in vivo. We implanted ~2000 human islets under the kidney capsule of STZ-rendered diabetic NOD/scid mice. Islet recipients were provided with water containing BrdU with, or without, lesogaberan (0.08 mg/ml) or GABA (6 mg/ml) for 12 days. The lesogaberan dose was chosen based on the results of previous preclinical studies in GERD models [26, 34] and our pilot dosing studies. All islet recipients, including controls given plain water, quickly became normoglycemic after receiving the islet graft and maintained normoglycemia throughout the experimental period. There was no significant difference in their food and water consumption (~4 ml/day), as well as body weights among these groups of mice (data not shown).

Immunofluorescent staining indicated that treatment with GABA significantly enhanced human β-cell replication (Figure 2), similar to previous observations [14, 16]. Lesogaberan treatment also significantly increased the frequency of BrdU+insulin+ and Ki67+insulin+ islet β-cells relative to that in human islets from the control mice (Figure 2). There was no significant difference in the percentages of replicative β-cells between the lesogaberan-treated and GABA-treated groups of mice. Hence, activation of peripheral GABAB-Rs effectively promotes human islet β-cell replication in vivo.

3.3. Oral Lesogaberan Limits Human Islet Cell Apoptosis following Islet Transplantation

Following human islet transplantation, the islets are subjected to hypoxic, metabolic, and inflammatory stressors which cause the apoptosis of a large proportion of islet cells within the first few days after implantation [35, 36]. We examined the ability of lesogaberan administration to limit islet cell apoptosis in a human islet xenograft model. We implanted STZ-rendered hyperglycemic NOD/scid mice with human islets under their kidney capsule and placed them on plain water or water containing lesogaberan or positive control GABA. Two days later, their kidneys were removed and tissue sections were stained by TUNEL and anti-insulin antibodies (Figure 3). In comparison with mice given plain water, treatment with GABA significantly protected human islet cells from apoptosis, consistent with previous observations [14, 16]. Furthermore, oral feeding with lesogaberan significantly reduced the percentages of apoptotic islet cells (Figure 3(b)) and increased the frequency of insulin+ β-cells in human islet grafts (Figure 3(c)). Thus, lesogaberan-mediated activation of GABAB-Rs limits islet cell apoptosis in transplanted human islets, consistent with previous islet cell survival studies with the prototypic GABAB-R-specific agonist baclofen, a drug unsuited for long-term human use [10, 12, 14].

4. Discussion

The modulation of GABA-Rs on β-cells is emerging as a new strategy to help promote human β-cell survival and replication in the context of T1D. Although GABA is safe for human consumption, its pharmacokinetics may be suboptimal. There are a number of available drugs that have been in wide clinical use to modulate GABA-Rs on CNS neurons; however, their CNS effects raise concerns for long-term diabetes treatment. We chose to test lesogaberan’s potential for diabetes treatment based on (1) its high affinity for GABAB-Rs, (2) its peripheral restriction circumvents CNS effects, and (3) its apparent safety in early clinical studies.

Our initial studies showed that lesogaberan at low dosages (30 and 10 nM) increased human islet cell proliferation in vitro by about 2-3-fold (resp.). This promitotic effect was abrogated by a GABAB-R antagonist, confirming that the effect was mediated through GABAB-Rs. The proliferating islet cells are likely to be primarily β-cells because β-cells may be the only islet cell type that express functional GABAB-Rs and α-cell transdifferentiation requires long-term GABAA-R activation [22].

After implanting human islets into scid mice, lesogaberan significantly increased β-cell replication in the islet grafts. The level of lesogaberan-induced β-cell replication in vivo was similar to that induced by GABA at the dosages used in our model and similar to the maximum level of β-cell replication that takes place shortly after birth in humans [37]. The activation of β-cell GABAB-Rs causes the opening of potassium channels, release of Ca2+ from intracellular storage, PKA activation, and Ca2+-dependent activation of PI3K-Akt and CREB (reviewed in [14]). It is notable that lesogaberan promoted β-cell replication as effectively as GABA (which activates both GABAB-Rs and GABAA-Rs) which may be due to its superior pharmacokinetics. Our short-term treatments with lesogaberan and GABA should not have induced α-cell transdifferentiation (which became detectable after 2 months of GABAA-R activation [22, 23]), and the small increase they induced in β-cell replication should not alter islet size. Finally, we observed that lesogaberan treatment significantly preserved human islet cells from apoptosis in human islet grafts.

It is thought that the amount of residual β-cell mass following T1D onset is a major factor determining the success of interventive therapy such that even a short-term treatment with lesogaberan may help preserve residual β-cell mass and thereby improve the outcome of interventive therapies. Indeed, GABA treatment enhanced β-cell replication and survival in newly diabetic NOD mice [11, 16], demonstrating that GABA-R activation can be beneficial in an autoimmune context even when there is little residual β-cell mass. It is worth noting that using FDA guidelines for scaling mouse doses to the equivalent human dosage (http://www.fda.gov/downloads/Drugs/.../Guidances/UCM078932.pdf), the lesogaberan dose we used was about 2- to 7-fold lower than the doses used in phase IIb GERD clinical trials [27, 32, 33]. This suggests that it may be possible to use lower dosage lesogaberan for diabetes treatment.

Conceivably, long-term lesogaberan treatment may lead to increased β-cell mass in T1D patients if autoimmune responses can be sufficiently controlled. In regard to controlling β-cell autoimmunity, recent studies indicate that activation of GABAB-Rs on immune cells has anti-inflammatory effects and can ameliorate collagen-induced arthritis and contact dermatitis in mouse models [38, 39]. Therefore, lesogaberan may also have anti-inflammatory effects that help control the pathogenic autoreactive T-cell responses that mediate β-cell destruction in T1D. It will be of interest to further investigate how activation of GABAB-Rs modulates the functions of different types of immunocompetent cells, and this may be a fertile area for new anti-inflammatory drug development. Additionally, lesogaberan may be combined with other immune modulators to potentially increase therapeutic effects, as was shown by the synergistic effect of combining GABA and antigen-specific immunotherapy to reverse hyperglycemia in newly diabetic NOD mice [16].

5. Conclusions

We found that the GABAB-R agonist lesogaberan promoted human islet cell proliferation in vitro, as well as β-cell replication and islet cell survival in vivo, as effectively as GABA. Accordingly, GABAB-R agonists may provide a new drug class to help maintain residual β-cell mass and function after diabetes onset. Our findings also suggest that including lesogaberan in the drug regimen following clinical human islet transplantation for even a brief period may reduce β-cell loss due to stressors and may thereby reduce the number of islets required to achieve insulin independence. Lesogaberan’s apparent safety and pharmacokinetic profile make it an excellent candidate for testing in clinical trials.

Conflicts of Interest

The authors declare that there is no duality of interest associated with this manuscript.

Acknowledgments

The authors thank the IIDP for providing isolated human islets. This work was supported by a grant from the JDRF (17-2013-403) and the National Institutes of Health (DK092480) to Daniel L. Kaufman.

References

  1. S. Bonner-Weir, W. C. Li, L. Ouziel-Yahalom, L. Guo, G. C. Weir, and A. Sharma, “β-Cell growth and regeneration: replication is only part of the story,” Diabetes, vol. 59, no. 10, pp. 2340–2348, 2010. View at: Publisher Site | Google Scholar
  2. R. N. Kulkarni, E. B. Mizrachi, A. G. Ocana, and A. F. Stewart, “Human β-cell proliferation and intracellular signaling: driving in the dark without a road map,” Diabetes, vol. 61, no. 9, pp. 2205–2213, 2012. View at: Publisher Site | Google Scholar
  3. P. Rorsman, P. O. Berggren, K. Bokvist et al., “Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels,” Nature, vol. 341, no. 6239, pp. 233–236, 1989. View at: Publisher Site | Google Scholar
  4. M. Braun, R. Ramracheya, M. Bengtsson et al., “γ-Aminobutyric acid (GABA) is an autocrine excitatory transmitter in human pancreatic β-cells,” Diabetes, vol. 59, no. 7, pp. 1694–1701, 2010. View at: Publisher Site | Google Scholar
  5. A. Reetz, M. Solimena, M. Matteoli, F. Folli, K. Takei, and P. De Camilli, “GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion,” The EMBO Journal, vol. 10, no. 5, pp. 1275–1284, 1991. View at: Google Scholar
  6. M. Braun, A. Wendt, B. Birnir et al., “Regulated exocytosis of GABA-containing synaptic-like microvesicles in pancreatic β-cells,” The Journal of General Physiology, vol. 123, no. 3, pp. 191–204, 2004. View at: Publisher Site | Google Scholar
  7. J. Taneera, Z. Jin, Y. Jin et al., “γ-Aminobutyric acid (GABA) signalling in human pancreatic islets is altered in type 2 diabetes,” Diabetologia, vol. 55, no. 7, pp. 1985–1994, 2012. View at: Publisher Site | Google Scholar
  8. R. W. Olsen and A. J. Tobin, “Molecular biology of GABAA receptors,” The FASEB Journal, vol. 4, no. 5, pp. 1469–1480, 1990. View at: Google Scholar
  9. B. Bettler, K. Kaupmann, J. Mosbacher, and M. Gassmann, “Molecular structure and physiological functions of GABA(B) receptors,” Physiological Reviews, vol. 84, no. 3, pp. 835–867, 2004. View at: Publisher Site | Google Scholar
  10. B. Ligon, J. Yang, S. B. Morin, M. F. Ruberti, and M. L. Steer, “Regulation of pancreatic islet cell survival and replication by γ-aminobutyric acid,” Diabetologia, vol. 50, no. 4, pp. 764–773, 2007. View at: Publisher Site | Google Scholar
  11. N. Soltani, H. Qiu, M. Aleksic et al., “GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 28, pp. 11692–11697, 2011. View at: Publisher Site | Google Scholar
  12. J. Tian, H. Dang, Z. Chen et al., “γ-Aminobutyric acid regulates both the survival and replication of human β-cells,” Diabetes, vol. 62, no. 11, pp. 3760–3765, 2013. View at: Publisher Site | Google Scholar
  13. G. J. Prud'homme, Y. Glinka, C. Hasilo, S. Paraskevas, X. Li, and Q. Wang, “GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone,” Transplantation, vol. 96, no. 7, pp. 616–623, 2013. View at: Publisher Site | Google Scholar
  14. I. Purwana, J. Zheng, X. Li et al., “GABA promotes human β-cell proliferation and modulates glucose homeostasis,” Diabetes, vol. 63, no. 12, pp. 4197–4205, 2014. View at: Publisher Site | Google Scholar
  15. J. Tian, H. Dang, B. Middleton, and D. L. Kaufman, “Clinically applicable GABA receptor positive allosteric modulators promote β-cell replication,” Scientific Reports, vol. 7, no. 1, p. 374, 2017. View at: Publisher Site | Google Scholar
  16. J. Tian, H. Dang, A. V. Nguyen, Z. Chen, and D. L. Kaufman, “Combined therapy with GABA and proinsulin/alum acts synergistically to restore long-term normoglycemia by modulating T-cell autoimmunity and promoting β-cell replication in newly diabetic NOD mice,” Diabetes, vol. 63, no. 9, pp. 3128–3134, 2014. View at: Publisher Site | Google Scholar
  17. J. Tian, H. Dang, and D. L. Kaufman, “Combining antigen-based therapy with GABA treatment synergistically prolongs survival of transplanted β-cells in diabetic NOD mice,” PLoS One, vol. 6, no. 9, article e25337, 2011. View at: Publisher Site | Google Scholar
  18. M. Braun, A. Wendt, K. Buschard et al., “GABAB receptor activation inhibits exocytosis in rat pancreatic β-cells by G-protein-dependent activation of calcineurin,” The Journal of Physiology, vol. 559, Part 2, pp. 397–409, 2004. View at: Publisher Site | Google Scholar
  19. A. Wendt, B. Birnir, K. Buschard et al., “Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring β-cells,” Diabetes, vol. 53, no. 4, pp. 1038–1045, 2004. View at: Google Scholar
  20. N. L. Brice, A. Varadi, S. J. Ashcroft, and E. Molnar, “Metabotropic glutamate and GABA(B) receptors contribute to the modulation of glucose-stimulated insulin secretion in pancreatic beta cells,” Diabetologia, vol. 45, no. 2, pp. 242–252, 2002. View at: Publisher Site | Google Scholar
  21. S. J. Bailey, M. A. Ravier, and G. A. Rutter, “Glucose-dependent regulation of γ-aminobutyric acid (GABAA) receptor expression in mouse pancreatic islet α-cells,” Diabetes, vol. 56, no. 2, pp. 320–327, 2007. View at: Google Scholar
  22. N. Ben-Othman, A. Vieira, M. Courtney et al., “Long-term GABA administration induces alpha cell-mediated beta-like cell neogenesis,” Cell, pp. 31523–31529, 2016. View at: Google Scholar
  23. J. Li, T. Casteels, T. Frogne et al., “Artemisinins target GABAA receptor signaling and impair alpha cell identity,” Cell, vol. 168, no. 1-2, article e115, pp. 86–100, 2017. View at: Publisher Site | Google Scholar
  24. J. Li, Z. Zhang, X. Liu et al., “Study of GABA in healthy volunteers: pharmacokinetics and pharmacodynamics,” Frontiers in Pharmacology, vol. 6, p. 260, 2015. View at: Publisher Site | Google Scholar
  25. D. B. Tower and E. Roberts, Eds., Inhibition in the nervous system and GABA, Pergamon Press, New York, 1960.
  26. A. Lehmann, M. Antonsson, A. A. Holmberg et al., “(R)-(3-Amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action,” The Journal of Pharmacology and Experimental Therapeutics, vol. 331, no. 2, pp. 504–512, 2009. View at: Publisher Site | Google Scholar
  27. N. J. Shaheen, H. Denison, K. Bjorck, M. Karlsson, and D. G. Silberg, “Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial,” Gut, vol. 62, no. 9, pp. 1248–1255, 2013. View at: Publisher Site | Google Scholar
  28. C. Alstermark, K. Amin, S. R. Dinn et al., “Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors,” Journal of Medicinal Chemistry, vol. 51, no. 14, pp. 4315–4320, 2008. View at: Publisher Site | Google Scholar
  29. M. Niazi, S. Skrtic, M. Ruth, and A. A. Holmberg, “Pharmacokinetic profile of lesogaberan (AZD3355) in healthy subjects: a novel GABA(B)-receptor agonist reflux inhibitor,” Drugs in R&D, vol. 11, no. 1, pp. 77–83, 2011. View at: Publisher Site | Google Scholar
  30. B. Fransson, D. G. Silberg, M. Niazi, F. Miller, M. Ruth, and A. A. Holmberg, “Effect of food on the bioavailability of lesogaberan given as an oral solution or as modified-release capsules in healthy male volunteers,” International Journal of Clinical Pharmacology and Therapeutics, vol. 50, no. 4, pp. 307–314, 2012. View at: Google Scholar
  31. G. E. Boeckxstaens, H. Beaumont, V. Mertens et al., “Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease,” Gastroenterology, vol. 139, no. 2, pp. 409–417, 2010. View at: Publisher Site | Google Scholar
  32. G. E. Boeckxstaens, H. Beaumont, J. G. Hatlebakk et al., “A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial,” Gut, vol. 60, no. 9, pp. 1182–1188, 2011. View at: Publisher Site | Google Scholar
  33. M. Niazi, D. G. Silberg, F. Miller, M. Ruth, and A. A. Holmberg, “Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects,” Drugs in R&D, vol. 10, no. 4, pp. 243–251, 2010. View at: Publisher Site | Google Scholar
  34. L. Branden, A. Fredriksson, E. Harring, J. Jensen, and A. Lehmann, “The novel, peripherally restricted GABAB receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs,” European Journal of Pharmacology, vol. 634, no. 1–3, pp. 138–141, 2010. View at: Publisher Site | Google Scholar
  35. J. A. Emamaullee and A. M. Shapiro, “Factors influencing the loss of beta-cell mass in islet transplantation,” Cell Transplantation, vol. 16, no. 1, pp. 1–8, 2007. View at: Google Scholar
  36. A. M. Davalli, Y. Ogawa, C. Ricordi, D. W. Scharp, S. Bonner-Weir, and G. C. Weir, “A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice,” Transplantation, vol. 59, no. 6, pp. 817–820, 1995. View at: Google Scholar
  37. B. E. Gregg, P. C. Moore, D. Demozay et al., “Formation of a human β-cell population within pancreatic islets is set early in life,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 9, pp. 3197–3206, 2012. View at: Publisher Site | Google Scholar
  38. S. Huang, J. Mao, B. Wei, and G. Pei, “The anti-spasticity drug baclofen alleviates collagen-induced arthritis and regulates dendritic cells,” Journal of Cellular Physiology, vol. 230, no. 7, pp. 1438–1447, 2015. View at: Publisher Site | Google Scholar
  39. B. Duthey, A. Hubner, S. Diehl, S. Boehncke, J. Pfeffer, and W. H. Boehncke, “Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis,” Experimental Dermatology, vol. 19, no. 7, pp. 661–666, 2010. View at: Publisher Site | Google Scholar

Copyright © 2017 Jide Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

909 Views | 403 Downloads | 3 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.